Ramucirumab: preclinical research and clinical development

Ramucirumab (IMC-1121B, LY3009806), a fully humanized monoclonal antibody directed against the extracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2), is a new therapeutic option that selectively inhibits the human VEGFR-2 with a much greater affinity than its natural ligand...

Descripción completa

Detalles Bibliográficos
Autores principales: Aprile, Giuseppe, Rijavec, Erika, Fontanella, Caterina, Rihawi, Karim, Grossi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218907/
https://www.ncbi.nlm.nih.gov/pubmed/25378934
http://dx.doi.org/10.2147/OTT.S61132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4218907/
https://www.ncbi.nlm.nih.gov/pubmed/25378934
http://dx.doi.org/10.2147/OTT.S61132

Ejemplares similares